|
|
 | | | |
- close
- close
- close
- close
Albany Molecular Research Inc (AMRI) |
Benzinga
Jun 12
Comment
In a report published Wednesday, Sterne Agee analyst Greg T. Bolan resumed coverage on Albany Molecular Research (NASDAQ: AMRI) with a Buy rating and $15.00 price target.
In the report, Sterne Agee noted, “From a revenue perspective, we...
Benzinga
Jun 5
Comment
AMRI (NASDAQ: AMRI), a leading
global contract research and manufacturing organization, has announced that
the Board of Directors has unanimously voted to separate the role of
Chairman and Chief Executive Officer and has named William S. Marth,...
StreetInsider.com
May 7
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Albany+Molecular+Research+%28AMRI%29+Reports+Q1+EPS+of+%240.23/8310989.html for the full story.
Benzinga
Mar 6
Comment
In a report published Wednesday, Sterne Agee reiterated its Buy rating on Albany Molecular Research (NASDAQ: AMRI), and raised its price target from $8.50 to $12.00.
Sterne Agee noted, “We are raising our EPS estimates for CY13 and CY14 to...
StreetInsider.com
Feb 12
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Albany+Molecular+Research+%28AMRI%29+Posts+Q4+adj.-EPS+of+17c%3B+Issues+Strong+FY13+Outlook/8083132.html for the full story.
Benzinga
Feb 11
Comment
AMRI (NASDAQ: AMRI) announced
today that it has signed an exclusive license agreement with Chai
Therapeutics, LLC for the development of ALB 109564(a), AMRI's novel tubulin
inhibitor compound in late Phase I testing for the treatment of cancer....
Benzinga
Jan 8
Comment
AMRI (NASDAQ: AMRI) announced
today that Richard A. Saffee has been promoted to the newly created role of
Vice President and General Manager of Large Scale Manufacturing, effective
immediately. He will continue to report to Steven R. Hagen, Ph.D.,...
FierceBiotech
Dec 3
Comment
CRO AMRI ($AMRI) is closing up its R&D shop in Bothell, WA, and shipping the site's biology capabilities to its drug discovery operation in Singapore. The Bothell plant employs 24 people, AMRI said in a statement, and the cost-cutting measure is...
Benzinga
Nov 30
Comment
AMRI (NASDAQ: AMRI)
announced today that as a next step in its SMARTSOURCING™ strategy it has
taken further actions to expand and better integrate its in vitro biology
services with its total drug discovery service platform.
(Logo:...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
